Raloxipirus Tablet

Adult dose

Once daily, 1 tablet orally.

This medication may increase the risk of venous thromboembolism, where blood clots form in the blood vessels and can block them, so patients at risk for venous thromboembolism should carefully weigh the risks and benefits before administration. If restricted movement occurs, this medication should be discontinued and resumed only after movement has returned to normal following recovery. This medication is primarily metabolized in the liver, so it is not recommended for patients with impaired liver function, and those with elevated liver function test results should be monitored more closely during treatment. It has not been confirmed to be safe for premenopausal women and should not be used. While this medication does not affect the occurrence of myocardial infarction or stroke in postmenopausal women at high risk for cardiovascular disease, the risk of death due to stroke may be slightly increased, thus caution is needed for patients with a history of stroke. This medication should not be used for the purpose of preventing cardiovascular diseases, and concomitant use with systemic estrogen is not recommended. Women who are pregnant or may become pregnant, as well as nursing mothers, should not use this medication as it may harm the fetus or newborn. Patients with certain conditions, such as a history of venous thromboembolism, liver dysfunction, unexplained uterine bleeding, or symptoms of endometrial cancer, should not use this medication. Patients with genetic metabolic disorders such as lactose intolerance should not take this medication. Patients with high serum triglyceride levels, renal impairment, or restricted movement should be administered this medication carefully, and should consult their physician if necessary. During the use of this medication, side effects such as leg cramps, facial flushing, cold symptoms, and peripheral edema may occur, so patients should alert healthcare professionals about any unusual symptoms. This medication may interact with other drugs, so patients currently taking other medications should inform their doctor or pharmacist. It should not be used by pregnant or nursing women and is intended solely for postmenopausal women. It is not used in children as safety and efficacy have not been established. In the case of overdose, symptoms such as dizziness, leg cramps, and vomiting may occur, so it is important to adhere to the prescribed dosage and administration. This medication should be stored out of reach of children and should not be transferred to other containers.

Serious side effects

Deep vein thrombosis, pulmonary embolism, retinal vein thrombosis, superficial venous thrombophlebitis, stroke, death associated with venous thromboembolism (VTE), thrombocytopenia, hypertension, headache including migraines, rash, arterial thromboembolism, retinal vein occlusion, stroke, serious allergic reactions, severe skin reactions, respiratory issues, liver abnormalities (jaundice), severe neurological symptoms, severe swelling or urinary disturbances.

Mild side effects

• Vasodilation (flushing)
• leg cramps
• cold symptoms
• peripheral edema
• nausea
• vomiting
• abdominal pain
• indigestion
• slight decrease in platelet count
• moderate elevation of AST and ALT

This medication should be stored in a closed container to protect it from air and moisture, and it is recommended to store it at room temperature between 1 to 30 degrees Celsius.

Appearance

Yellow round film-coated tablet

Package unit

30 tablets (10 tablets/PTP X 3)